Most people with latent Mycobacterium tuberculosis infection can partly develop active tuberculosis (TB). Therefore, diagnosis of this condition bears significance in early TB prevention. To date, the main methods for diagnosis of latent TB infection (LTBI) include tuberculin skin test and interferon γ release test. These two methods feature their own advantages and disadvantages. Although new diagnostic markers continually emerge, no uniform diagnostic criteria are available for TB detection. This study summarizes several methods for diagnosis of LTBI and new related markers and their application value in clinical practice.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1 Dye C Scheele S Dolin P et al. Consensus statement. Global burden of tuberculosis: estimated incidence prevalence and mortality by country. JAMA 1999 282(7): 677-686.
2 Shen HB Wang HH. Reactions advances in therapeutic anti-tuberculosis vaccines. J Microbes Infect 2010 5(2):111-116.
3 Chen XX Yang QT Xu LM et al. Diagnosis of latent Mycobacterium tuberculosis infection in undergraduate student of Shenzhen using ELISPOT and PPD skin test. J Clin Pulmonary Med 2009 14(6):737-738.
4 Alvarez-Leon EE Espinosa-Vega E Santana-Rodriguez E et al. Screening for tuberculosis infection in Spanish healthcare workers: Comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test. Infect Control Hosp Epidemiol 2009 30(9):876-883.
5 Yang HL Kruh-Garcia NA Dobos KM. Purified protein derivatives of tuberculin--past present and future. FEMS Immunol Med Microbiol 2012 66(3):273-280.
6 Yang HL Troudt J Grover A et al. Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection. Infect Immun 2011 79(2):716-723.
7 Skinner MA Ramsay AJ Buchan GS et al. A DNA prime-live vaccine boost strategy in mice can augment INF-γ responses to mycobacterial antigens but dose not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology 2003 108(4):548-555.
8 Codecasa L Mantegani P Galli L et al. An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection. J Clin Microbiol 2006 44(6):1944-1950.
9 Peng Z Zhu CM. Research progress of Mycobacterium tuberculosis RD1. Chongqing Med 2011 40(1):89-98.
10 Hougardy JM Schepers K Place S et al. Heparin-binding-hemagglutinin-induced INF-gamma release as a diagnostic tool for latent tuberculosis. PLoS One 2007 2(10): e926.
11 Brock I Munk ME Kok-Jensen A et al. Performance of whole blood IFN-γ test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 2001 5(5):462-467.
12 Pai M Zwerling A Menzies D et al. Systematic review: Tcell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008 149(3):177-184.
13 Nienhaus A Schablon A Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection-analysis of discordant results when compared to the tuberculin skin test. PloS One 20083(7): e2665. DOI:10.1371/journal.pone.0002665
14 Liu FR Ye LX. The progress in diagnosis of latent tuberculosis infection in HIV-infected populations. J Pub Health Prev Med 200617(5):49-51.
15 Corbett EL Watt CJ Walker N et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003 163(9):1009-1021.
16 Wang H Tan Y Zhu XY et al. Use of INF-γ release assay in latent tuberculosis infection diagnosis in general and HIV-infected populations. Chin J Microb Immunol 2009 29(11): 1037-1041.
17 Zeng XA. Primary analysis of HIV infection in patients with pulmonary tuberculosis. Chin J AIDS/STD 2004 10(5):354-355.
18 Talati NJ Gonzalezn-Diaz E Mutemba C et al. Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assay. BMC Infect Dis 201111:264.
19 Dixon WG Hyrich KL Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010 69(3):522-528.
20 Sellam J Hamdi H Roy C et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007 66(12):1610-1615.
21 Segall L Covic A. Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol 2010 5(6):1114-1122.
22 Sayarlioglu H Gül M Eren Dagli C et al. QuantiFERON-TB Gold test for screening latent tuberculosis infection in hemodialysis patients. Tuberk Toraks 2011 59(2):105-110.
23 Christopoulos AI Diamantopoulos AA Dimopoulos PA et al. Risk factors for tuberculosis in dialysis patients: aprospective muti-center clinical trial. BMC Nephrol 200910:36.
24 Dobler CC McDonald SP Marks GB. Risk of tuberculosis in dialysis patients: a nationwide cohort study. PLoS One 201 6(12): e29563.
25 Nienhaus A Schablon A Costa JT et al. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 2011 11:247.
26 Pooran A Booth H Miller RF et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 201010:7.
 Day CL Abrahams DA Lerumo L et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in human is associated with mycobacterial load. J Immunol 2011187(5):2222-2232.
28 Ruhwald M Bodmer T Maier C et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J 2008 32(6):1607-1615.
29 Kabeer BS Raja A Raman B et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect Dis 2011 11:135.